BET inhibitors ablate PAX3‐FOXO1 function, providing a rationale for their use in the treatment of fusion‐positive ARMS patients (Gryder et al, 2017, 2019, 2020). The gene discussed is FOXO1; the disease is alveolar rhabdomyosarcoma.